CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon

Bulletin Express03-26

China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.

The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.

The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129458795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129458795","market":"us","top_or_hot":-1,"title":"CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-26 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1129458795","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129458795","pubTimestamp":1774523095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药子公司华润双鹤发行人民币10亿元三年期债券，票面利率为1.65%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.\nThe offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.\nThe transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129458795","isCrawlerRequest":true}